This publication presents evidence that countries around the world still apply tariffs and nontariff measures that increase prices and limit the availability of health-related products such as pharmaceuticals, vaccines, and medical equipment. The case for liberalizing trade in these products is therefore strong. In addition the authors show that improving trade facilitation performance, using the World Trade Organization’s Trade Facilitation Agreement as a starting point, can be linked to improved handling of health-related products such as vaccines which, in turn, would boost usage. In the last part of the paper the authors study the price differences for insulin across countries.